Colin P.N. Dinney, MD, presented “Therapy for High Risk NMIBC” during the 42nd Annual Ralph E. Hopkins Urology Seminar on February 1, 2023, in Jackson Hole, Wyoming.
How to cite: Dinney, Colin P.N. “Therapy for High Risk NMIBC.” February 1, 2023. Accessed Aug 2024. https://grandroundsinurology.com/therapy-for-high-risk-nmibc/
Therapy for High Risk NMIBC – Summary
Colin P.N. Dinney, MD, defines the criteria that categorize patients as high-risk, such as tumor grade, size, and recurrence history. He underscores the importance of early and accurate diagnosis using advanced imaging techniques and molecular markers, which play a crucial role in guiding treatment decisions.
He focuses on Bacillus Calmette-Guérin (BCG) therapy, the gold standard for high-risk NMIBC. Dr. Dinney reviews BCG’s mechanisms of action, administration protocols, and factors influencing its efficacy. He also addresses the challenges posed by BCG shortages and the emergence of BCG-unresponsive disease, highlighting the need for alternative therapeutic strategies.
Further, Dr. Dinney discusses the potential of immune checkpoint inhibitors, targeted therapies, and gene therapy in the context of high-risk NMIBC. He presents data from recent clinical trials that demonstrate the promising results of these innovative approaches in achieving durable responses and reducing recurrence rates.
About The 42nd Annual Ralph E. Hopkins Urology Seminar:
The Ralph E. Hopkins Urology Seminar is a multi-day meeting focused on training urologists in the latest in assessing, diagnosing, and treating urologic conditions in the clinical setting. Updates are provided on urologic cancers, stone disease, urologic reconstruction, female urology, infertility, sexual function, emerging surgical techniques, and general urology. The 42nd iteration of the meeting took place from February 1st to 4th, 2023, in Jackson Hole, Wyoming.
For further educational activities from this conference, visit our collection page.
ABOUT THE AUTHOR
Colin P. N. Dinney, MD, is Chairman of the Department of Urology, Division of Surgery, and also co-chairs the Genitourinary Steering Committee for the Bladder Task Force at the University of Texas MD Anderson Cancer Center in Houston, Texas. Dr. Dinney earned his MD from the University of Winnipeg, Canada and completed his residency in urology at Dalhousie University in Halifax, before moving to Houston to begin his work with the MD Anderson Cancer Center. He has published over twenty peer-reviewed articles and currently serves as a professor in the Department of Cancer Biology at the University of Texas. He is recognized as one of Houston’s top urologists and has been awarded numerous honors, such as the 2015 Society of Urologic Oncology Medal. His other appointments include serving as Co-Chair of the Orthopedic Oncology Chair Search Committee, as well as past-director of the Bladder Organ Site Committee of the Society of Urologic Oncology Clinical Trials Consortium.
